Treatment Effect of Intense Pulsed Light and Thermal Pulsation Therapy on Meibomian Gland Dysfunction-associated Dry Eye Disease: a Randomized Trial

NCT ID: NCT06745089

Last Updated: 2024-12-20

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

45 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-07-13

Study Completion Date

2024-03-10

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this clinical trial is to understand novel treatment methods for meibomian gland dysfunction (MGD)-associated dry eye disease (DED) by comparing two treatment modalities- intense pulsed light (IPL) and thermal pulsation therapy (TPT), to find out the difference of their therapeutic mechanisms and treatment effects, so that eye doctors can give more precise advice to the patients when making treatment decisions.

The main questions it aims to answer are:

* What subtype of meibomian gland dysfunction (MGD) better responds to which treatment modality?
* How long do the treatment effects last?

Researchers will compare each group (IPL and TPT) to a control group treated with eyedrops.

\* Do combined treatment of IPL or TPT with eyedrops show better outcomes than only eyedrops?

Participants will:

* Receive different treatment for 2 months according to the group they were randomly allocated to.
* Visit the clinic for checkups after 1 and 3 months after completing the treatment sessions.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Dry Eye Disease (DED) Meibomian Gland Dysfunction

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

IPL arm

Group Type EXPERIMENTAL

Intense pulsed light

Intervention Type DEVICE

Intense pulsed light exerts photothermal, photochemical effects, and photobiomodulation on meibomian glands.

TPT arm

Group Type EXPERIMENTAL

thermal pulsation therapy

Intervention Type DEVICE

Thermal pulsation therapy utilizes local heating and massage on the eyelids.

Control arm

Group Type ACTIVE_COMPARATOR

Ocular lubricant

Intervention Type DRUG

Ocular lubricants moisturize the ocular surface.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Intense pulsed light

Intense pulsed light exerts photothermal, photochemical effects, and photobiomodulation on meibomian glands.

Intervention Type DEVICE

thermal pulsation therapy

Thermal pulsation therapy utilizes local heating and massage on the eyelids.

Intervention Type DEVICE

Ocular lubricant

Ocular lubricants moisturize the ocular surface.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* individuals diagnosed with meibomian gland dysfunction (MDG)-associated dry eye disease (DED) that are suitable for intense pulsed light (IPL) and thermal pulsation therapy (TPT)

Exclusion Criteria

* ocular surgery or trauma in the recent 3 months
* ocular infection
* eyelid abnormalities (e.g., entropion, ectropion, lagophthalmos, severe ptosis or trichiasis)
* blepharospasm
* eyelid tumor
* severe meibomian gland atrophy
* allergic to topical anesthetics
* sunbathe in recent one month
* periocular fillers
Minimum Eligible Age

20 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Nobel Eye Institute

UNKNOWN

Sponsor Role collaborator

National Science and Technology Council, Taiwan

OTHER_GOV

Sponsor Role collaborator

National Health Research Institutes, Taiwan

OTHER

Sponsor Role collaborator

National Yang Ming Chiao Tung University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Wen-Chuan Kuo

Professor and Director, Institute of Biophotonics, National Yang Ming Chiao Tung University

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Institute of Biophotonics, National Yang Ming Chiao Tung University

Taipei, , Taiwan

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Taiwan

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

IRB number: YM111073F

Identifier Type: -

Identifier Source: org_study_id